Quantitative metabolomics services for biomarker discovery and validation.
Specializing in ready to use metabolomics kits.
Your source for quantitative metabolomics technologies and bioinformatics.
Loader

Filter by Pathway Type:



Showing 61 - 70 of 605359 pathways
SMPDB ID Pathway Name and Description Pathway Class Chemical Compounds Proteins

SMP0145338

Pw147006 View Pathway

5-Aminolevulinic acid Drug Metabolism Pathway

Metabolic

SMP0145362

Pw147030 View Pathway

5-Hydroxy-L-tryptophan Drug Metabolism Pathway

Metabolic

SMP0125617

Pw127181 View Pathway

5-Oxoprolinase Deficiency

5-Oxoprolinase deficiency, also called OPLAHD, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of glutathione metabolism caused by a defective 5-oxoprolinase. 5-Oxoprolinase catalyzes the conversion of 5-oxoproline into glutamate which is an important neurotransmitter. This disorder is characterized by a large accumulation of 5-oxoproline in the urine. Symptoms of the disorder include enterocolitis, mental retardation, kidney stone formation, and hypoglycemia. 5-Oxoprolinase deficiency has been reported in approximately 8 people.
Disease

SMP0000500

Pw000476 View Pathway

5-Oxoprolinase Deficiency

5-Oxoprolinase deficiency, also called OPLAHD, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of glutathione metabolism caused by a defective 5-oxoprolinase. 5-Oxoprolinase catalyzes the conversion of 5-oxoproline into glutamate which is an important neurotransmitter. This disorder is characterized by a large accumulation of 5-oxoproline in the urine. Symptoms of the disorder include enterocolitis, mental retardation, kidney stone formation, and hypoglycemia. 5-Oxoprolinase deficiency has been reported in approximately 8 people.
Disease

SMP0000143

Pw000074 View Pathway

5-Oxoprolinuria

5-Oxoprolinuria (5-Oxoprolinase deficiency) is a result of a defect in the gamma-glutamyl cycle due to either 5-oxoprolinase or glutathione synthetase deficiency. In the case of glutathione synthetase deficiency, the glycine is not incorporated into gamma-glutamylcysteine. In the case of 5-oxoprolinase, however, pyroglutamic acid accumulates. Symptoms include anemia, mental retardation, metabolic acidosis, respiratory distress and urolithiasis.
Disease

SMP0125615

Pw127179 View Pathway

5-Oxoprolinuria

5-Oxoprolinuria (5-Oxoprolinase deficiency) is a result of a defect in the gamma-glutamyl cycle due to either 5-oxoprolinase or glutathione synthetase deficiency. In the case of glutathione synthetase deficiency, the glycine is not incorporated into gamma-glutamylcysteine. In the case of 5-oxoprolinase, however, pyroglutamic acid accumulates. Symptoms include anemia, mental retardation, metabolic acidosis, respiratory distress and urolithiasis.
Disease

SMP0145324

Pw146992 View Pathway

9-cis-Retinoic acid Drug Metabolism Pathway

Metabolic

SMP0127980

Pw129599 View Pathway

99mTc-14 F7 Mab Drug Metabolism

Metabolic

SMP0130144

Pw131763 View Pathway

A-dmDT390-bisFv(UCHT1) Drug Metabolism

Metabolic

SMP0000737

Pw000714 View Pathway

Abacavir Action Pathway

Abacavir (also known as Ziagen or Epzicom) is an antiviral agent that is used for treating HIV/AID. Cellular enzyme converts abacavir to its activate metabolite, carbovir triphosphate, for inhibiting HIV-1 reverse transcriptase (RT) by competing with dGTP, which is the natural substrate of RT. Without HIV-1 reverse transcriptase, complementary DNA (cDNA) could not be generated; therefore, viral DNA couldn't be completed.
Drug Action
Showing 61 - 70 of 65005 pathways